These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 19065543

  • 21. Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen.
    Jain S, Patrick AJ, Rosenthal KL.
    Vaccine; 2010 Oct 08; 28(43):7070-80. PubMed ID: 20723627
    [Abstract] [Full Text] [Related]

  • 22. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.
    Rollman E, Hinkula J, Arteaga J, Zuber B, Kjerrström A, Liu M, Wahren B, Ljungberg K.
    Gene Ther; 2004 Jul 08; 11(14):1146-54. PubMed ID: 15103320
    [Abstract] [Full Text] [Related]

  • 23. Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
    Hinz A, Schoehn G, Quendler H, Hulsik DL, Stiegler G, Katinger H, Seaman MS, Montefiori D, Weissenhorn W.
    Virology; 2009 Aug 01; 390(2):221-7. PubMed ID: 19539967
    [Abstract] [Full Text] [Related]

  • 24. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses.
    Gzyl J, Bolesta E, Wierzbicki A, Kmieciak D, Naito T, Honda M, Komuro K, Kaneko Y, Kozbor D.
    Virology; 2004 Jan 20; 318(2):493-506. PubMed ID: 14972518
    [Abstract] [Full Text] [Related]

  • 25. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
    Li J, Chen X, Jiang S, Chen YH.
    Biochem Biophys Res Commun; 2008 Nov 07; 376(1):60-4. PubMed ID: 18762167
    [Abstract] [Full Text] [Related]

  • 26. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM.
    J Virol; 2005 Jun 07; 79(11):7059-67. PubMed ID: 15890945
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.
    Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, Geelen E, van der Helm E, Lemckert A, Gillissen G, Verhaagh S, Custers J, Zuijdgeest D, Berkhout B, Bakker M, Quax P, Goudsmit J, Havenga M.
    J Virol; 2004 Dec 07; 78(23):13207-15. PubMed ID: 15542673
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.
    Eckhart L, Raffelsberger W, Ferko B, Klima A, Purtscher M, Katinger H, Rüker F.
    J Gen Virol; 1996 Sep 07; 77 ( Pt 9)():2001-8. PubMed ID: 8810996
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
    Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, Berkower I, Wyatt R.
    Virology; 2008 Mar 30; 373(1):72-84. PubMed ID: 18155743
    [Abstract] [Full Text] [Related]

  • 34. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP, Young KR, Ross TM.
    Virology; 2007 Feb 20; 358(2):334-46. PubMed ID: 17011011
    [Abstract] [Full Text] [Related]

  • 35. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
    Wang X, Uto T, Akagi T, Akashi M, Baba M.
    J Virol; 2007 Sep 20; 81(18):10009-16. PubMed ID: 17609261
    [Abstract] [Full Text] [Related]

  • 36. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.
    Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, Polonis VR, Alving CR.
    AIDS; 2009 Oct 23; 23(16):2069-77. PubMed ID: 19710597
    [Abstract] [Full Text] [Related]

  • 37. ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.
    Zhang G, Chen YH.
    Immunobiology; 2003 Oct 23; 207(4):259-64. PubMed ID: 12952348
    [Abstract] [Full Text] [Related]

  • 38. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.
    Visciano ML, Diomede L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, Buonaguro FM, Lopalco L, Buonaguro L.
    Vaccine; 2011 Jul 12; 29(31):4903-12. PubMed ID: 21596074
    [Abstract] [Full Text] [Related]

  • 39. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
    Xiao Y, Liao M, Lu Y, Dierich MP, Chen YH.
    Immunobiology; 2000 Jan 12; 201(3-4):323-31. PubMed ID: 10776789
    [Abstract] [Full Text] [Related]

  • 40. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP, Bryson S, Nieva JL, Pai EF.
    J Mol Biol; 2008 Dec 12; 384(2):377-92. PubMed ID: 18824005
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.